Upperton Pharma Solutions
Michael Mellor-Clark is an experienced executive with significant expertise in commercial leadership within the life sciences sector. Currently serving as Chief Commercial Officer at Upperton Pharma Solutions since April 2025, Michael previously held similar roles at Concept Life Sciences and PathoQuest. At BioReliance, from January 2014 to April 2022, Michael advanced through various positions, culminating as Senior Director and Head of Strategic Partnership Accounts, where responsibilities included the development of the Key Account Function and establishment of sales teams in Europe. Earlier in the career, Michael worked as a Commercial Development Officer at Inveresk Research, focusing on biosafety testing and laboratory services. Michael holds a BSc (Hons) in Molecular Biology from The University of Edinburgh and completed the General Management Program at Cranfield School of Management.
This person is not in any teams
This person is not in any offices
Upperton Pharma Solutions
Upperton Pharma Solutions is a specialist CDMO (contract development and manufacturing organisation) providing formulation and dosage form development services to the biotechnology and pharmaceutical industries. We offer our clients a complete development service, from early feasibility studies to process optimisation, scale up and clinical trial (GMP / IMP) manufacturing. We are able to enhance the performance and delivery of our client’s products by utilising an extensive range of formulation technologies. In particular we have world leading expertise and know-how in pharmaceutical spray dryings, probably the most versatile and fastest growing technology in the industry. We have experience of working with a range of dosage forms and the expertise to develop the most challenging of molecules. Our formulation work is supported by a comprehensive range of analytical services for product testing and ICH stability studies. Upperton has an extensive, multinational client-base, ranging from virtual and small start-ups to global pharma companies. We pride ourselves on our client-focused, flexible approach and scientific excellence.